[68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients

Submitted: July 18, 2020
Accepted: July 28, 2020
Published: March 18, 2021
Abstract Views: 1119
PDF: 628
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Objectives: Clinical approach of prostate cancer (PCa) biochemical recurrence (BCR) is an ever-changing topic. Prostate-specific membrane antigen positron emission tomography ([68Ga]Ga-PSMA-11 PET-CTPSMA PET-CT) has shown good potential in this field. The aim is to evaluate PSMA PET-CT detection rate in PCa BCR and assess its impact on clinical outcome.
Material and methods: Out of 319 patients with PCa who underwent PSMA PET-CT between October 2015 and June 2019, 70 had developed BCR after treatment with curative intent. Two groups were created: one with BCR after surgery (RP group) (N: 48; 68.6%) and other with BCR after radiotherapy (RT group) (N: 22; 31.4%). Clinical, analytical, pathological and PSMA PET-CT results were evaluated.
Results: Initial age was different between groups (p = 0.008). RP patients were mainly at intermediate risk (85.1% vs 42.9%, p = 0.001) while RT patients were at low risk of recurrence (8.5% vs 47.6%, p = 0.001). In RP and RT groups, PSMA PETCT detected, respectively, pelvic relapse in 31.3% and 63.6%, and extrapelvic relapse in 18.8% and 31.8%. Salvage treatment was performed in 61.9% (n = 26) of RP patients and in 15% (n = 3) of RT patients, p < 0.001. Of RP patients submitted to salvage treatment, 59.1% achieved complete remission. Concerning these patients, local radiotherapy led to complete remission in 68.4% (n = 13). Of RT patients submitted to salvage treatment, two had complete remission and one had partial remission.Concerning detection rate, PSMA PET-CT was positive for pelvic relapse when pre-PET PSA ≥ 0.8 ng/mL (RP) or ≥ 2.3 ng/mL (RT) and for extrapelvic relapse when PSA ≥ 0.4 ng/mL (RP) or ≥ 3.5 ng/mL (RT), p > 0.05.
Conclusions: Biochemical persistence rate after salvage therapy was similar (30-40%). The cut-off PSA values for pelvic relapse detected on PSMA PET-CT were ≥ 0.8 ng/mL (RP) and ≥ 2.3 ng/mL (RT).

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-86. DOI: https://doi.org/10.1002/ijc.29210
Freedland SJ, Humphreys EB, Mangold L, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostatespecific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25:1765-71. DOI: https://doi.org/10.1200/JCO.2006.08.0572
Toussi A, Stewart-Merrill SB, Boorjian SA, et al. Standardizing the definition of biochemical recurrence after radical prostatectomy- What prostate specific antigen cut point best predicts a durable increase and subsequent systemic progression? J Urol. 2016;195:1754-9. DOI: https://doi.org/10.1016/j.juro.2015.12.075
Roach M, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol; Phys. 2006; 65:965-74. DOI: https://doi.org/10.1016/j.ijrobp.2006.04.029
Van den Broeck, van den Bergh R, Briers E, et al. Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel Recommendations Eur Urol Focus. 2020; 6:231-234. DOI: https://doi.org/10.1016/j.euf.2019.06.004
Eissa A, Elsherbiny A, Coelho RF, et al. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol. 2018; 70:462-478. DOI: https://doi.org/10.23736/S0393-2249.18.03081-3
Albisinni S, Artigas C, Aoun F, et al. Clinical impact of 68 Gaprostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int. 2017; 120:197-203. DOI: https://doi.org/10.1111/bju.13739
Emmett L, van Leeuwen PJ, Nandurkar R, et al. Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. J Nucl Med. 2017;58:1972-6. DOI: https://doi.org/10.2967/jnumed.117.196683
Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017; 44:1258-68
Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis Eur Urol 2016; 70:926-37.
Meredith G, Wong D, Yaxley J, et al. The use of 68 G a-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016; 118:49-55. DOI: https://doi.org/10.1111/bju.13616
Mottet N, van den Bergh R, Briers E, et al. EAU - EANM -ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2020.
Aboagye EO, Kraeber-Bodéré F. Highlights lecture EANM 2016: “Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine”. Eur J Nucl Med Mol Imaging. 2017; 44:1559-1574. DOI: https://doi.org/10.1007/s00259-017-3704-6
Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigenavid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020; 77:403-417. DOI: https://doi.org/10.1016/j.eururo.2019.01.049
Budaus L, Leyh-Bannurah SM, Salomon G, et al. Initial experience of 68Ga-PSMA PET/CT imaging in high risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016; 69:393-6. DOI: https://doi.org/10.1016/j.eururo.2015.06.010
Demirci E, Kabasakal L, Sahin OE, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019; 40:86-91. DOI: https://doi.org/10.1097/MNM.0000000000000942
Sanli Y, Kuyumcu S, Sanli O, et al. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med. 2017;31:709-717. DOI: https://doi.org/10.1007/s12149-017-1207-y
Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive (68) Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016; 70:926-937. DOI: https://doi.org/10.1016/j.eururo.2016.06.021
Eder M, Neels O, Müller M, et al. Novel preclinical and radiopharmaceutical aspects of [(68)Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals. 2014;7:779-96. DOI: https://doi.org/10.3390/ph7070779
Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014; 65:124-137. DOI: https://doi.org/10.1016/j.eururo.2013.09.046
Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid68Ga-PSMA Ligand PET/CT in 248 Patients with BiochemicalRecurrence After Radical Prostatectomy. J Nucl Med. 2015; 56:668-74. DOI: https://doi.org/10.2967/jnumed.115.154153
Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017; 44:1258-68. DOI: https://doi.org/10.1007/s00259-017-3711-7
Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018; 74:179-90. DOI: https://doi.org/10.1016/j.eururo.2018.03.030
Murphy DG, Sweeney CJ, Tombal B.Gotta catch ‘em al,” or do we? Pokemet approach to metastatic prostate cancer Eur Urol. 2017; 72:1-3. DOI: https://doi.org/10.1016/j.eururo.2017.02.036

How to Cite

Carvalho, J. ., Nunes, P., da Silva, E. T., Silva, R., Lima, J., Quaresma, V., & Figueiredo, A. (2021). [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients. Archivio Italiano Di Urologia E Andrologia, 93(1), 21–25. https://doi.org/10.4081/aiua.2021.1.21